Human EGFR-targeting monoclonal antibody (mAb) therapy such as cetuximab has been approved for clinical use in patients with colorectal cancers and head and neck squamous cell carcinomas. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.